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The ethical promotion of medicinals has developed into a controversial 
issue. The ever increasing number of medicinal products available world-
wide has caused the marketing of medicinals to follow courses so complex 
in nature that ethics are only too often cast aside. This dissertation, for 
this reason, will aim to evaluate the role of the pharmacist in the field 
of contemporary medical representation. It will also attempt to evaluate 
current practices by which medicinals are marketed and advertised in 
Malta. It will also aim to correlate these practices with appropriate 
legislation in an effort to ensure that as far as possible an ethical 
approach to drug marketing will prevail locally. 
Part 1 
The Surveys 
Survey A was distributed to 100 medical representatives to evaluate 
(a) their predominant required qualifications 
(b) the training which they must undergo 
(c) the professions which they predominantly target 
(d) the nature of the information they disseminate 
(e) the methods employed in order to achieve optimum results 
(f) the measures taken to ensure that the methods they employ remain 
within established frameworks of professionalism. 
Survey B was distributed to 150 community pharmacists to determine 
(a) the relationship between the presence of a resident physician in a 
community pharmacy and visits by mcdical repre3entative3 to 
pharmacists 
(b) the prevalent opinion as to the value of medical representatives' 
work to the service they offer to patients 
(c) the nature and methods by which information is imparted to them 
by medical representatives 
(d) the belief,' or otherwise, that certain methods employed by 
medical representatives could result in the promotion of medication 
of inferior quality 
(e) their opinion, or otherwise, that a significant number of medical 
representatives reach unethical agreements with physicians in 
order to induce them to prescribe their products. 
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Survey C was distributed to 350 medical practitioners to evaluate 
(a) their belief, or otherwise, that a degree in pharmacy is a requisite 
for professional and ethical medical representation 
(b) the extent of the influence that medical representatives are 
capable of exerting on their prescribing habits 
(c) their belief, or otherwise, that the medical representative is 
indeed the optimum source of up-to-date information 
(d) their opinions to whether medical representation symbolises an 
ethical concept, or not 
Part B 
The Sit-In 
The motives behind the holding of the sit-in study were: 
(a) the silent observation of the presentations delivered by medical 
representatives to physicians 
(b) the analysis of content of the presentations in general 
(c) the distinction, when possible, between the diversities in approach 
and content and extent of knowledge between pharmacist and non-
pharmacist representatives. 
In all, 20 such sit-in sessions were held. The medical representatives 
under observation were divided into two groups. Group 1 members were 
pharmacist medical representatives and group 2 members were medical 
representatives who did not possess a degree in pharmacy. 
The observers were four in each sit-in study and comprised, a medical 
practitioner, a pharmacist and two senior medical representatives. Of 
these two representatives, one was a pharmacist and the other possessed 
a degree in marketing. The observers attended the sit-ins with the full 
knowledge of the medical representatives being subjected to the trial. 
They were seated in a position behind the medical representatives in 
order that they could inconspiciously complete standard questionnaires. 
The questionnaires sought to evaluate 
(a) the format of the presentation 
(b) its contents 
(c) the methods by which the medical representatives dealt with any 
questions asked by physicians 
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(d) several multiple choice questions enquired about specific events 
and messages 
(e) the methods by which medical representatives participated in 
any ensuing discussions 
Part 3 
The Product Update Bulletin 
A Product Update Bulletin featuring the most recent medicinal products 
on the local market and on established products which are now being used 
for new indications or via different dosage regimens was set up. This 
involved visiting several local agents of leading pharmaceutical 
companies and enquiring whether they wished to submit entries to this 
periodical which, in the event of its successful publication would be 
compiled and published regularly on a trimesterly bases. The companies 
participating were requested to pay a nominal fee of Lm15 for every 
product submitted for publication. 
The motive behind this bulletin is to bring to foremost members of the 
Health Care Team including pharmacists, physicians and dentists up-to-
date data which included: 
(a) name of drug and legal status 
(b) local company 
(c) name of medical representative 
(d) composition 
(e) properties 
(f) indications 
(g) pharmacokinetics 
(h) dosage and administration 
(i) special points to note 
(j) undesirable effects 
(k) contra-indications 
0) precautions 
(m) warnings 
(n) interactions 
(0) storage instructions 
(p) presentation and price 
The data submitted by local representatives of the participating 
pharmaceutical companies was edited and compiled in a manner suitable 
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for eventual publication in newsletter format. It was aimed to present 
each write up in as concise a manner as possible. This was done in order to 
ensure a supply of information th<;lt li/hile being comprehensive would not 
necessitate the undue consumption of time to read and for this reason, 
each product submitted was allocated ~a one-half page space in the 
bulletin. The first issue presented a total of 26 products. 
This bulletin also introduced a scheme by which any Adverse Drug 
Reaction (ADR) encountered by pharmacists and physicians during the 
course of their clinical practice could be recorded. 
Discussion of Results 
Part 1 
The Surveys 
Although an evaluation of Survey A distributed to medical 
repres~ntatives indicated a predominance of pharmaci~ts among the 
locally practising medical representative population (68.85%), a 
remaining significant amount of currently practising medical 
representatives do not possess a degree in pharmacy. This fact gains 
significance, when it is considered that from an evaluation of the results 
obtained in survey B distributed to community pharmacist, 92.74% 
considered a degree in pharmacy to be a requisite for a licence to practice 
as a medical representative since this gives them the background in 
pharmacology that is a necessity if the former are to present a credible 
and professional source of information as medicinals. The above 
sentiments were echoed in Survey C distributed to medical practItIoners 
were 79.19% believed medical representation and a degree in pharmacy 
to be mutually exclusive. 
The medical representatives currently practising locally, in their great 
majority 90.16%, undergo company training prior to being allowed to start 
their work. Such training lasts between 1 - 2 weeks (80.32%) and .deals 
mainly with individual product information and selling skills (65.47%). 
Local medical representatives, in their majority 54.1%, concentrate their 
efforts primarily on physicians 'since they believe these latter to be 
primary promoters of prescription products. 32% believed the 
pharmacists and physicians to be of equal importance and 13.1 % 
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targetted their products at sectors of health professions depending on the 
range of products they were currently detailing. 
Medical representatives favoured personal interviews as the primary 
tool for drug promotion. This method was selected by only 71.3% of the 
medical representatives interviewed in the case of pharmacists as 
compared to the 100% response in the case of physicians. The second most 
favoured medium was exhibitions held in conjunction with medical 
conferences and symposia in the case of pharmacists (44.26%), but in the 
case of physicians the supply of samples and literature emerged as second 
preference. 
Community pharmacists found medical representatives to be of great use 
to them for various reasons. 34.68% agreed that medical representatives 
are the ideal medium to become acquainted with products; 30.65% agreed 
that medical representatives help in the reacquaintance with products 
which although have been established on the market are now being used 
for new indications or via different dosage regimens and 16.12% agreed 
that medical representatives present a comparative outlook of products 
available on the market. Physicians also value medical representatives 
and 68.68% claimed to be influenced in their prescribing habits by 
detailing procedures. 
Medical representatives are of the firm conviction that the physicians 
should be their primary target. This belief is confirmed when it is taken 
into account that 63.93% of medical representatives promote their 
products at private clinics. 
75% of .community pharmaci~t~ interviewed agreed ,thal unelhical 
arrangements do exist between certain medical representatives and 
practising physicians and on being questioned further, 53.03% proposed 
the introduction of legislation whereby prescribing is effected utilising 
generic names only; 12.09% proposed the introduction of stricter controls 
by local health authorities and 8.87% proposed the introduction of better 
systems for the education of both medical representatives and 
physicians. 
The majority of medical representatives (72.13%) emerged as being 
averse to the advertising of OTC drugs, stating that such practices 
encouraged self-medication (40.98%) and also that they gave rise to 
abuse (26.23%). A further 4.92% considered OTC advertising unethical. 
A lesser portion of medical representatives supported OTe advertising 
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and believed that it was a source of patient education (13.12%) and that 
it disseminated useful drug information to the general public (6.56%). A 
further 8.19% approved drug advertising as long as this was limited to 
GTe categories. 
All the community pharmacists interviewed agreed that GTe 
preparations should not be awarded media coverage, and in the course of 
expressing their views, they named several salient reasons in 
justification: 
(i) OTe advertising leads to self-medication (34.68%) 
(ii) GTe advertising encourages drug abuse/misuse (33.06%) 
(iii) Such advertising is often misleading (16.94%) 
(iv) GTe advertisements do not mention specific causes (15.32%). 
Similar views prevailed among the medical population being sampled. 
A 100% negative attitude towards GTe advertising was recorded:-
(i) GTe advertising lead to self-medication (41.21 %) 
(ii) OTe advertising increases the demand for such medication 
(18.68%) 
(iii) GTe advertising leads to misuse of the drugs to patients (14.84%) 
(iv) GTe advertisements, if they must exist at all, should be restricted 
exclusively to medical and pharmaceutical journals (9.34%) 
(v) Advertisements for OTe medication do not offer the public 
sufficient information (6.58%) 
(vi) The information often offered to the general public is not relevant 
to the needs of the general public (4.95%) 
(vii) It i3 not within lay-men'!> jUlisJkLion to select a medicinal 
appropriate to their condition (4.40%) 
85.25% of medical representatives interviewed agreed that a connection 
existed between GTe; advertising and the artificial demand for non-
prescription medicines. Approximately, 95% of both pharmacists and 
physicians expressed such views. . 
The majority of medical representatives (83.27%) believed that by 
exerting restrictions on drug advertisements, the sales of GTe medications 
would drop and thus, this would precipitate higher prices for consumers. 
A minority of 16.73% believed that by restricting patient orientated 
advertisements excessive competition in the field of GTe preparations 
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would automatically drop resulting, therefore, in lower prices for 
consumers. Most community pharmacists (42.74%) postulated that 
advertising or its absence would produce no effect on consumer prices owing 
to the fact that in Malta prices are fixed by health authorities. A 
further 37.10% predicted an increase in price in the event of restricting 
advertising owing to the fact that sales would automatically drop. The 
remaining 20.16% held that in restricting advertisements, consumer prices 
would drop since its absence would render drug manufacturing cheaper. 
Medical practitioners, predicted in their great majority (75.42%) that 
consumer prices would increase in the absence of OTe advertising since 
this would cause the drug mailing of literature to be more expensive than 
advertising. 24.58% predicted the price to decrease for consumers owing 
to the fact that a reduction in advertising to them was synonymous with a 
cut in competition for identical markets. 
Part 2 
The Sit-In 
On average, 3 drugs were presented by the medical representatives to the 
physicians at anyone time and in both the sitting and the standing 
presentations printed material such as advertisements, reprints of 
publications, booklets or patient aids were often handed out. Samples 
were almost exclusively distributed at each presentation and the doctors 
being detailed appeared very appreciative of these latter, on occasion 
putting forward specific requests. No visible differences between 
pharmacist and non-pharmacist medical representatives were noted up 
to this point. 
During the course of the study it was noted by the observers that the 
indications for the drug were almost always given but negative aspects of 
.the drug including side-effects and contra-indications were omitted. This 
was particularly true, however, in cases of 
(a) sessions which necessitated very concise presentations owing to the 
fact that sometimes physicians were very busy 
(b) the non-pharmacist representatives. 80% of pharmacist medical 
representatives as compared to 41 % of non-pharmacist medical 
representatives outlined the incidence of possible unwanted effects, 
contra-indications and potential interactions to the physician they 
were detailing 
29 
In general, relatively few questions were asked by doctors to medical 
representatives and in fact the observers recorded a total of 30 questions 
asked by these latter in twenty sit-in sessions. The percentage 
distribution of questions asked by doctors to medical representatives in 
accordance with the topic (N=30) included:-
Pharmacokinetics, dose, composition,etc 24 
Efficiency, indications, etc 20 
Economy (price, how supplied) 17 
Side-effects and contra-indications 13 
Disease or its therapy in general 13 
Competitive drugs 8 
Non-medical areas 5 
TOTAL 100 
Both pharmacists and non-pharmacist medical representatives were 
well versed with respect to their own products, however, differences were 
observed when physicians started discussions that delved too deeply into 
the pharmacology of competitive preparations. 
Part 3 
The Product Update Bulletin 
On being asked in Surveys Band C about the introduction and usefulness of 
a product update bulletin featuring the most recent medicinal products on 
the local market there was an 84.53% and 72.64% response in favour from 
pharmacists and physicians respectively. 
The Product Update Bulletin was well received by both the pharmacists 
and physicians with 80% of the recipients requesting further issues. 
The response obtained on the part of the local distributors was indicative 
of the fact that these recognised the value of the Bulletin in the 
widespread dissemination on their medicinals. 
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PRODUCT 
UPDATE 
BULLETIN 
-1-' &k& 
This Bulletin which will be published periodicollv 
by the Pharmacy Department will 
formation on medicinal products 
recently on the local market and on 
lished products which are now being used 
new indications or via different dosage regi· 
mens. 
The ideo behind this Bulletin is to bring to 
pharmacists and physicians, alike, " ..... t,,·.1r 
data which will include: 
. Name of Company. 
Nome of mQdicol reprA5p.ntntive. 
. Name of product and legal status. 
· Composition· Properties. 
· Indications· Pharmacokinetics. 
· Undesirable effects. 
· Dosage and method of 
administration. 
· Contraindicotions . Warnings. 
· Precautions. 
• Interactions· Overdosage. 
· Special points to note. 
· Storage in~tructions. 
• Presentation and price. 
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Recent 
Medicinal 
Products 
Allerglobuline 
Augmentin Double Strength ..................... 3 
Aurorix 
Cloritine .......................................................... 4 
Com feel Dressings 
Coversyl. ....................................................... 5 
Dormicum 
Droxor ........................................................... 6 
Foverin 
Inhiboce ....................................................... 7 
Isoptin SR 
Lomisil ............................................................ 8 
Loriom 
Medonol.. ..................................................... 9 
Mucofolk 
Nobecutone .............................................. 10 
Nuelin SA 
Proctofoom HC ......................................... ll 
Stilnox 
Tenormin ..................................................... 12 
Tilode 
Voslorel. ...................................................... 13 
Zestril 
Zofron ........................................................... 14 
Zolodex 
Zovirox BOO ............. .................................... 15 
The Product Update Bulletin besides proving its use to the foremost 
members of the Health Care Team, as a comprehensive source of up-to-
date information on the most recent medicinals on the local market, also 
enabled them to offer a better service to the public. 
A net profit of Lm300 was recorded after the general dissemination of the 
first issue. 
It is estimated, thus, that a profit of over Lm1,200 can be made yearly 
assuming a trimesterly publication of the product update bulletin. 
This study has thus proved the feasibility of the organisation of such a 
project, and it has been determined furthermore that it would make both 
professional and financial sense if publication of the product update 
bulletin were to be taken up permanently by the Pharmacy Department. 
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